Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world treatment patterns and outcomes of patients with myelodysplastic syndrome by line of therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

JAJacob AmbroseABAndrew J. BelliCZChristina M. Zettler

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows poor overall survival in myelodysplastic syndrome patients, indicating a need for new therapies.

Key Points

  • Real-world overall response rate was 31.1% for first-line hypomethylating agents in myelodysplastic syndrome patients, a concerning statistic.
  • Patients with higher IPSS-R scores had significantly worse overall survival, with 11.1 months for high scores compared to 54.9 months for very low scores.
  • Analysis of treatment patterns was conducted using electronic health records from the COTA real-world database, highlighting key demographic findings.
  • The findings underscore the necessity for innovative treatment approaches for high-risk myelodysplastic syndrome patients.

Cite This Study

Ambrose et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd82https://doi.org/10.1182/blood-2025-601
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world patient characteristics, treatment patterns, and outcomes in patients with myelodysplastic syndromes2025
  2. 2Differential trends in survival after allogeneic transplantation for MDS and MDS/MPN in a real-world experience2025
  3. 3Temporal trends in overall survival among patients with high-risk MDS: Insights from the spanish MDS registry (RESMD)2025
  4. 4Real-world clinical characteristics and outcomes of patients with myelodysplastic syndrome with TP53 mutation2025
  5. 5Trends in transplantation for patients with myelodysplastic syndrome across recent decades: A registry-based study on behalf of the chronic malignancies working of the EBMT2025